异基因干细胞移植治疗多发性骨髓瘤

Allogeneie stem cell transplantation in multiple myeloma

异基因干细胞移植是惟一可能治愈多发性骨髓瘤（MM）的临床方法。较高的移植相关死亡率（TRM）限制了清髓性异基因干细胞移植在临床的广泛应用；非清髓性异基因干细胞移植降低了TRM，但疾病复发和进展的风险却增加；自体一非清髓性异基因干细胞串联移植，在降低TRM的同时，可有效减少疾病的复发和进展。目前临床上亦存在很多可能提高MM移植疗效的新方法。

Allogeneic stem cell transplantation is the only treatment which may cure multiple myeloma （MM）. The high transplantation related mortality （TRM） limits the wide clinical application of myeloablative allogeneic stem cell transplantation. Non-myeloablative allogeneic stem cell transplantation can reduce the TRM, but the risk of relapse and progress of the disease may get increased. Auto- nonmyeloablative allogeneic stem cell tandem transplantation can reduce both the TRM and the relapse and progress of the disease. At present, there exist many new methods which may improve the effect of allogeneic stem cell transplantation for MM in clinical.